1. Pink Sheet
  2. >>Product Reviews
  3. >>Approvals

Pharma Showing More Interest In Conditional Approvals; Back On EU Expert Group Agenda

 
• By Neena Brizmohun

The number of conditional marketing authorizations granted in the EU reached an all-time high in 2016, with eight products approved under the early access pathway. In 2017, so far, a CMA has been granted for Roche’s product Alecensa, and Shire’s Natpar has been recommended for approval under the pathway. In addition, a European Commission expert group that has been exploring how to improve the CMA process and eliminate the negative perceptions surrounding its use is examining a key report on how the pathway is faring.

capsules
Interest in the conditional authorization pathway is rising, says the EMA • Source: Shutterstock

The number of conditional marketing authorizations granted in the EU last year rose to an all-time high, against a backdrop of efforts by regulators to improve the early access pathway and eliminate the negative perceptions that have surrounded its use.

Eight products received a CMA in 2016, twice as many than the highest number of CMAs granted in any given year since 2006, when the pathway was first used

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Product Reviews